Skip to main content
Explore URMC

Majed A. Refaai, M.D.

Contact Information

Phone Numbers

Office: (585) 276-3927

Fax: (585) 273-3003

URMFGA member of the University of Rochester Medical Faculty Group

groupAn Accountable Health Partner

assignmentAccepting New Patients

Faculty Appointments

Patient Care Setting



Dr. Refaai's clinical service is in Transfusion Medicine with subspecialty involvement in laboratory coagulation/thrombosis testing.


Dr. Refaai's recent studies have included: The in-vitro effect of ABO anti-bodies on platelet function; The correlation between cancer and tissue factor (TF) plasma concentrations and its role in developing DVT; The relationship between the circulating TF and the cancer tissue concentrations of TF in different types of mouse models; Beriplex phase IIIb drug study for bleeding patients with Warfarin overdose; Beriplex phase IIIb drug study for surgical patients who require a quick reversal of Warfarin; The effect of ABO non-identical blood products transfusion on platelet function (in-vivo); Platelet transfusion in patients with positive heparin-induced thrombocytopenia; Comparison of tissue factor pathway inhibitor (TFPI) concentration and activity in mononuclear cells from normal individuals versus patients with Paroxysmal Nocturnal Hemoglobinuria; Comparison of TFPI concentrations in normal mouse plasma and endothelial cells versus a diabetic mouse model; Analysis of fatty acid ethyl ester (FAEE) concentrations in binge drinking, chronic alcoholics, and postmortem biopsies.



  • Clinical Pathology/Laboratory Medicine - American Board of Pathology


MD | Syria - Aleppo Univ School of Medicine, Aleppo

Post-doctoral Training & Residency

07/01/2006 - 06/30/2007
Fellowship in Tranfusion Medicine at University of Texas Southwestern

06/30/2003 - 06/30/2006
Residency in Pathology at Barnes-Jewish Hospitals

04/01/1997 - 05/31/2003
Research in at Massachusetts General Hospital

VIEW ALL expand_more


Journal Articles

Boulware R, Refaai MA. "Why do patients with immune thrombocytopenia (ITP) experience lower bleeding events despite thrombocytopenia?" Thrombosis research.. 2020 Jan 15; 187:154-158. Epub 2020 Jan 15.

Schmidt AE, Sahai T, Refaai MA, Sullivan M, Curtis BR. "Severe Platelet Transfusion Refractoriness in Association with Antibodies Against CD36." . 2020 Jan 11; Epub 2020 Jan 11.

Schmidt AE, Israel AK, Refaai MA. "The Utility of Thromboelastography to Guide Blood Product Transfusion." American journal of clinical pathology.. 2019 Sep 9; 152(4):407-422.